SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook overshadowed its quarterly results, with soft PC demand and manufacturing constraints weighing on expectations and prompting analyst downgrades. Traders are divided between calling the selloff an overreaction and expecting further declines.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq and technology-stock selloff, amid concerns about AI valuations, heavy infrastructure spending and disappointing tech earnings, is driving discussion; Intels plunge is a frequent focus. Traders are split between expecting further losses and viewing the decline as an oversold correction, while claims of forced liquidations and geopolitical or election-related triggers remain speculative.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks sharp selloff despite beating earnings expectations, raising guidance and announcing a stock split dominates discussion, with traders pointing to broad tech and memory-stock weakness and fears that memory pricing and earnings growth may be nearing a cyclical peak. Many view the drop as an overreaction and are buying the dip, while others argue slowing growth and the memory cycle justify caution.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported Binance security breach and temporary withdrawal suspension have fueled selling and fears of contagion across crypto, adding pressure to Bitcoin amid a broader risk-off move. Traders disagree on whether the incident signals deeper exchange risks and more downside or is a buying opportunity, noting that Bitcoin itself was not directly hacked.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares plunged after its quarterly report paired strong results with a softer revenue outlook, slowing user growth and warnings that declining Google search referrals could pressure traffic; plans to test a logged-in-first experience added concern about losing casual visitors. Traders debate whether the selloff is an overreaction to temporary headwinds or reflects a deeper threat to Reddits user growth and advertising model.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor and tech selloff, led in part by Intels weak outlook and concerns about AI/PC demand, has hammered SOXLs 3x leveraged exposure. Traders are split between buying the dip for a relief bounce and warning that sector weakness and leverage-driven losses could deepen.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is drawing attention after a sharp selloff tied to DaVitas warning that DefenCaths post-TDAPA reimbursement contribution could fall significantly after Q1 2027, raising concerns about future adoption and revenue. Traders disagree over whether DaVitas preliminary estimate signals a real commercial risk or is outweighed by CMSs reimbursement outlook; some view the decline as an overreaction.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

IOVAs sharp selloff followed updated lifileucel lung-cancer trial data: the overall response rate was roughly in line with the prior update, while a retrospective biomarker-selected subgroup showed a much higher response rate, leaving investors debating the narrower opportunity, uncertain durability and FDA path. Traders also criticized managements presentation; some see the reaction as excessive and the precision-treatment strategy as promising, while others remain concerned about delayed validation and lost confidence in management.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

The move to a fresh 52-week high is centered on Q3 earnings expectations and continued BRIUMVI growth. Traders also speculate that buyout interest or short covering may be adding to momentum, though no acquisition is confirmed.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

DIA is under pressure amid a broad market selloff, with traders citing rising oil prices and escalating Middle East tensions alongside scrutiny of tech earnings and AI spending. The discussion is broadly bearish, though some traders point to market rotation and see pullbacks as buying opportunities.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces a poster presentation at the 2026 Annual NEALS Meeting on October 28th in Clearwater, Florida. NEALS (Network of Excellence for ALS...

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS...

Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced the company will be participating in a panel discussion at Chardan's...

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced full enrollment of the planned 120 participants in the Companys Phase...

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that the 100th patient has been enrolled in the Companys ongoing Phase...

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was...

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended June 30, 2026 and provides a...

Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?

Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial...

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 p.m. PT...

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing proprietary new therapies to enhance the function of regulatory T cells. Its pipeline includes Treg Modifying Biologics, Allogeneic Treg-Derived Exosomes, and Autologous Treg Cell Therapy. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

Coya Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.60
Prev Close	$3.98
Open	$4.00
Dividend Yield	0.00%
50-Day Moving Average	$4.64
Beta	1.21
Avg. Volume	144,895.68
PE Ratio	-3.98

52-Week High	$6.62
52-Week Low	$3.71
Market Capitalization	$93.36M
EPS (Annual)	-$1.27
Price to Book	2.16
Revenue Per Employee	$993,219.13

Feed

News

Sentiment

Earnings

Fundamentals

Info

COYA Fundamentals